Dallas, Texas--(Newsfile Corp. - February 10, 2026) - AB Science S.A. (ENXTPA: AB): Stonegate Capital Partners Initiates Coverage on AB Science S.A. (ENXTPA: AB). AB Science is a late-stage biotech advancing masitinib, an oral, selective tyrosine kinase inhibitor designed to modulate maladaptive neuroinflammation through mast-cell and microglia/macrophage pathways. The Company is positioning masitinib as an add-on therapy across ALS, progressive MS, and AD, while maintaining earlier-stage upside through AB8939 in AML. The combination of a treatment for ALS along with the optionality that comes with the rest of the Company's portfolio makes us excited to monitor the development of AB's Masitinib asset.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- ALS program supported by prior Phase 2b/3 data
- For progressive MS, the Phase 3 trial is authorizedin the US and 12 EU countries with ~94 sites initiating
- Financing supported by grants
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283417
Source: Reportable, Inc.
